Caroline Robert
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
- Immunology top 0.05%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 383
- Cancer Immunotherapy and Biomarkers 214
- CAR-T cell therapy research 151
- Cutaneous Melanoma Detection and Management 107
- Colorectal Cancer Treatments and Studies 48
-
- Melanoma and MAPK Pathways 223
- Protein Degradation and Inhibitors 23
- Co-authors
- James Larkin (62 shared papers)Dirk Schadendorf (116 shared papers)F. Stephen Hodi (43 shared papers)Alexander M.M. Eggermont (55 shared papers)Franck Carbonnel (20 shared papers)Omid Hamid (57 shared papers)Jedd D. Wolchok (41 shared papers)John B.A.G. Haanen (10 shared papers)
- Journals
- Journal of Clinical Oncology (164 papers)Annals of Oncology (81 papers)European Journal of Cancer (44 papers)Cancer Research (20 papers)Clinical Cancer Research (17 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Caroline Robert
635 papers receiving 43.0k citations
Caroline Robert's Hit Papers
Peers
Comparison fields: 5 of 181
- Oncology 24.8k
- Immunology 10.1k
- Dermatology 2.1k
- Molecular Biology 14.0k
- Cancer Research 2.6k
Countries citing papers authored by Caroline Robert
This map shows the geographic impact of Caroline Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Robert more than expected).
Fields of papers citing papers by Caroline Robert
This network shows the impact of papers produced by Caroline Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Robert. The network helps show where Caroline Robert may publish in the future.
Co-authors
The 25 scholars most cited alongside Caroline Robert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 661 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 1790 |
| 2 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Hit paper breakdown → | 2015 | 1617 |
| 3 | A decade of immune-checkpoint inhibitors in cancer therapy Hit paper breakdown → | 2020 | 1153 |
| 4 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1110 |
| 5 | Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab Hit paper breakdown → | 2017 | 1015 |
| 6 | Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer Hit paper breakdown → | 2005 | 971 |
| 7 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 930 |
| 8 | Removal of C.I. Basic Green 4 (Malachite Green) from aqueous solutions by adsorption using cyclodextrin-based adsorbent: Kinetic and equilibrium studies Hit paper breakdown → | 2006 | 908 |
| 9 | Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma Hit paper breakdown → | 2017 | 898 |
| 10 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Hit paper breakdown → | 2016 | 844 |
| 11 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 798 |
| 12 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Hit paper breakdown → | 2019 | 735 |
| 13 | Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study Hit paper breakdown → | 2006 | 715 |
| 14 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 706 |
| 15 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 659 |
| 16 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 651 |
| 17 | CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients Hit paper breakdown → | 2013 | 572 |
| 18 | Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab Hit paper breakdown → | 2015 | 520 |
| 19 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Hit paper breakdown → | 2017 | 513 |
| 20 | Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2020 | 460 |
About Caroline Robert
Caroline Robert is a scholar working on Oncology, Molecular Biology, Immunology, Dermatology and Organic Chemistry, having authored 661 papers that have together received 44.0k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (223 papers), Cancer Immunotherapy and Biomarkers (214 papers), CAR-T cell therapy research (151 papers), Cutaneous Melanoma Detection and Management (107 papers), Immunotherapy and Immune Responses (87 papers), Colorectal Cancer Treatments and Studies (48 papers), Click Chemistry and Applications (39 papers) and Protein Degradation and Inhibitors (23 papers). The work is most often cited by research in Oncology (24.8k citations), Immunology (10.1k citations), Dermatology (2.1k citations), Molecular Biology (14.0k citations) and Cancer Research (2.6k citations). Caroline Robert has collaborated with scholars based in France, United States and Germany. Frequent co-authors include James Larkin, Dirk Schadendorf, F. Stephen Hodi, Alexander M.M. Eggermont, Franck Carbonnel, Omid Hamid, Jedd D. Wolchok, John B.A.G. Haanen, Jeffrey S. Weber and Reinhard Dummer. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.